Clinical trial · Interventional
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
a Novel Dual-Targeting Molecular Probe TATE-RGD for the Diagnostic Integration of SSTR2 and αvβ3 Positive Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The US FDA approved a targeted somatostatin receptor 2 imaging agent, 68Ga-DOTATATE, in 2016. It has higher uptake in small cell lung cancer, pulmonary carcinoid, and medullary thyroid cancer. Integrin αvβ3 is highly expressed in some tumor cells and new blood vessels, making it an ideal target for targeted diagnosis and treatment of tumors and tumor vessels.68Ga-labeled DOTA-TATE-RGD is a new type of tumor-specific imaging agent developed by researchers based on the above foundation, which is used for targeted diagnosis and internal radiation therapy for patients with SSTR2 and αvβ3 positive tumors.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Iodine-resistant Thyroid Cancer | — | UNRESOLVED | — |
| Meningioma | Meningioma | ONTOLOGY_EXACT | 0.90 |
| NETs | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18-FDG | Drug | — | UNRESOLVED |
| 68Ga-TATE-RGD | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Experimental: 68Ga-TATE-RGD PET/ CT scan
- description
- About 30 patients with positive expression of somatostatin receptor SSTR2 and integrin receptor αvβ3 were included for PET imaging.
- interventionNames
- Drug: 68Ga-TATE-RGD
- Drug: 18-FDG
Primary outcomes (1)
- measure
- Tumor detection rate
- timeFrame
- through study completion, an average of half-year
- description
- comparing the number of tumor detected by 68Ga-TATE-RGD and18F-FDG PET/CT
Secondary outcomes (1)
- measure
- standardized uptake value (SUV) of tumor
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed various cancer patients; * 68Ga-TATE-RGD and 18F-FDG PET/CT within a week; * signed written consent. Exclusion Criteria: * known allergy against TATE-RGD; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
References
Publications (0)
Data not yet available